![ELF Score Banner head](/assets/images/_1530x530_crop_center-center_none/ELF-Score-Banner-head.png)
There’s an easy and
non-invasive way to
assess your risk of NASH
disease progression
condition called NASH, in which the liver builds up
excessive fat deposits, putting your health at risk.
![ELF Score Slide 1](/assets/images/_490x490_crop_center-center_none/ELF-Score-Slide-1.png)
Enhanced Liver Fibrosis (ELF™) Score
$310 CAD
Twenty percent of patients with NAFLD progress to nonalcoholic steatohepatitis (NASH), which is strongly linked to liver fibrosis and can lead to cirrhosis, liver transplantation, or even death.¹ Furthermore, 1 in 5 patients with advanced fibrosis progress to cirrhosis in 2.5 years.2 A simple blood test can determine the risk of NASH progression
Source:
1. Younossi Zm, Koenig A, Abdelatif D, Et Al. Global Epidemiology Of Nonalcoholic Fatty Liver Disease-Meta-Analytic Assessment Of Prevalence, Incidence, And Outcomes. Hepatology. 2016;64(1):73-84. Doi:10.1002/Hep.28431
2. Sanyal Aj, Harrison Sa, Ratziu V, Et Al. The Natural History Of Advanced Fibrosis Due To Nonalcoholic Steatohepatitis: Data From The Simtuzumab Trials. Hepatology. 2019;70(6):1913-1927. Doi:10.1002/Hep.30664
Benefits
- Non-invasive sample collection
- Confidential results in 7 to 10 days
Collection method
Blood sample – visit an Alpha Labs Patient Service Centre
About this test
![ELF Score Stat Image](/assets/images/_490x490_crop_center-center_none/ELF-Score-Stat-Image.png)
It is estimated that by 2030, NASH will be the #1 most frequent reason for liver transplants in the U.S.
Source: Charlton Mr, Burns Jm, Pedersen Ra, Et Al. Frequency And Outcomes Of Liver Transplantation For Nonalcoholic Steatohepatitis In The United States. Gastroenterology. 2011;141(4):1249-1253. Doi:10.1053/J.Gastro.2011.06.061